Multiple myeloma;Mnohočetný myelom

Klinicka Onkologie

Volumn 21, Issue SUPPL., 2008, Pages 187-189

  Krejci M ^a   Adam, Z ^a   Hajek R ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Diagnostics; Multiple myeloma; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; HUMAN; LABORATORY TEST; MULTIPLE MYELOMA; PROGNOSIS; REVIEW;

EID: 54249131812     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Adam Z, Bačovský J, Flochová E et al. Diagnostika a léčba mnohočetného myelomu. Doporučení vypracované Českou myelomovou skupinou, Myelomovou sekcí České hematologické společnosti a experty Slovenské republiky pro diagnostiku a léčbu mnohočetného myelomu. Transfúze a hematologie dnes 2005; 1: Suppl. 1, 3-51.
2. Attal M, Harouseau JL, Stoppa AM et al. High dose therapy in multiple myeloma: final analysis of prospective randomized study of the Intergroup Francais du Myelome (IFM 90). N Eng J Med 1996; 335:91-97.
3. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997, 89:789-793.
4. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with haematopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-1883.
5. Barlogie B, Tricot GJ, van Rhee F et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135:158-164.
6. Barosi G, Boccadoro M, Cavo M et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89:717-741.
7. Bergsagel PL. Epidemiology, etiology and molecular pathogenesis. In: Richardson PG, Anderson KC. Mutiple myeloma. London, Remedica Publishing, 2004; p. 1-24.
8. Durie B, Salmon S.: A clinical staging system for multiple myeloma. Cancer 1975; 36:842-852.
9. Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370:1209-1218.
10. Fonseca R, Blood E, Rue M et al. Clinical and biological implications of reccurent genomic aberrations in multiple myeloma. Blood 2003; 101:4569-4575.
11. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412-3420.
12. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749-757.
13. Krejci M, Hajek R, Adam Z et al. Significant improvement of long-term survival after autologous transplantation in multiple myeloma patiens: a single centre experience. Bone Marrow Transplant 2008; 41: Suppl. 1, Abstract R1358.
14. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367:825-831.
15. Rajkumar SV, Blood E, Vesole D et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
16. San Miguel JF, Schlag R, Khuageva N et al. MMY-3002: a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood 2007; 110: Abstract 76.
17. Smith A, Wisloff F, Samson D et al. Gudelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006; 132: 410-451.